Phase I Trial of Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma
Upon determination of eligibility, patients will be receive:
- Bortezomib
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
objective response rate
John D. Hainsworth, MD
Principal Investigator
Sarah Cannon Research Institute
United States: Food and Drug Administration
SCRI MM 06
NCT00193557
May 2004
January 2009
Name | Location |
---|---|
Florida Cancer Specialists | Fort Myers, Florida 33901 |
Tennessee Oncology, PLLC | Clarksville, Tennessee 37043 |